Dalbavancin for heart valve infections
Part of Heart & circulation, Infections clinical trials.
This study tests a new antibiotic called dalbavancin for treating infections of the heart valves. It may offer a simpler treatment option with fewer hospital visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed infection of the left side of the heart (mitral or aortic valve).
- The infection is caused by certain bacteria (staphylococci, streptococci, or enterococci) that can be treated with dalbavancin.
- You are not currently in severe shock or on a ventilator for blood pressure support.
- You have not had fever or positive blood cultures in the last 72 hours.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares taking antibiotics by mouth versus receiving antibiotics through a vein (outpatient IV) for an infection of the heart valve. It’s designed to see whether the oral option can work as well and safely, especially after initial treatment and surgery if needed.
This study looks at whether taking antibiotics before certain dental procedures helps prevent a serious heart infection in people who have a prosthetic heart valve or have had a heart infection before. It aims to find out if this common practice is effective.
This trial tests a combination of two antibiotics (ampicillin and ceftriaxone) to treat a heart valve infection caused by Enterococcus faecalis bacteria. It aims to see how well the medicine works and if it's safe.
This trial tests if adding bacteriophages (viruses that kill bacteria) to standard antibiotic treatment can help people with a serious heart valve infection called infective endocarditis. It may offer a new way to fight the infection.
This trial tests whether dalbavancin (an antibiotic given as a dose or doses) works as well as standard antibiotics to treat bloodstream infections related to a removed IV catheter caused by Staphylococcus aureus. It may help reduce treatment time and dosing complexity if you qualify.
This study tests a better way to give a long-acting antibiotic called dalbavancin for serious bacterial infections. Dalbavancin is given as an infusion and may allow you to leave the hospital sooner while still completing your antibiotic treatment.
Hear when a new Endocarditis, Bacterial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.